Showing results (41-50 of 165) with videos related to

Sort By:
Pageof 17
Cancer|May 15, 2007
Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphomaElias Jabbour, Chitra Hosing, Gregory Ayers, et al.
British Journal of Haematology|February 10, 2022
Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphomaIshan Roy, Gordon Smilnak, Madelyn Burkart, et al.
American Journal of Hematology|March 22, 2007
Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literatureAndres O Soriano, Michael A Thompson, Joan H Admirand, et al.
Hematological Oncology|June 13, 2023
Hematological Oncology journal women in lymphoma special issue: Latest updates in nodal peripheral T-cell lymphomaLimei Poon, Laurence de Leval, Siok Bian Ng, et al.
Chinese Clinical Oncology|March 2, 2019
The histological prevalence and clinical implications of folliculotropism and syringotropism in mycosis fungoidesClaudia Hossain, Tara Jennings, Robert Duffy, et al.
JAMA Network Open|March 12, 2020
Women's Representation in Leadership Positions in Academic Medical Oncology, Radiation Oncology, and Surgical Oncology ProgramsMudit Chowdhary, Akansha Chowdhary, Trevor J Royce, et al.
Cancer|June 18, 2011
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohortTomasz P Srokowski, James E Liebmann, Manuel R Modiano, et al.
Cancer|March 17, 2004
Thalidomide for patients with recurrent lymphomaBarbara Pro, Anas Younes, Maher Albitar, et al.
Leukemia & Lymphoma|September 14, 2020
Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphomaFelipe Samaniego, Peter McLaughlin, Sattva S Neelapu, et al.
Leukemia & Lymphoma|April 11, 2003
Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomasHoon K Lee, Richard B Wilder, Dan Jones, et al.
Pageof 17